Discontinuation report BLEPHAMIDE
| Report ID | 150359 |
| Drug Identification Number | 00807788 |
| Brand name | BLEPHAMIDE |
| Common or Proper name | Sulfacetamide/Prednisolone suspension |
| Company Name | ALLERGAN INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | PREDNISOLONE ACETATE SULFACETAMIDE SODIUM |
| Strength(s) | 0.2% 10% |
| Dosage form(s) | DROPS |
| Route of administration | OPHTHALMIC OPHTHALMIC |
| Packaging size | 5mL and 10mL |
| ATC code | S01CA |
| ATC description | ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMB |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2022-01-31 |
| Actual discontinuation date | |
| Remaining supply date | 2022-01-31 |
| Discontinuation status | To be discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Company contact information; Telephone number: 800-668-6424 Email address: MR-GENERAL_INQUIRY@allergan.com Website address: allergan.ca Postal address: 500-85 Enterprise Blvd, Markham, Ontario, L6G 0B5 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2021-12-02 | French | Compare |
| v1 | 2021-12-02 | English | Compare |
Showing 1 to 2 of 2